SHANGHAI, Aug. 28, 2026 /PRNewswire/ — Asieris Pharmaceuticals today released its 2026 Semi-Annual Report, showing comprehensive progress across all business segments. With the gradual realization of commercial launch and international expansion for its core products, the company is accelerating its transition from Biotech to Biopharma: CEVIRA®, the world’s…